CyGenica is revolutionizing intracellular drug delivery with GEENIE, a groundbreaking platform that combines cutting-edge innovation with unwavering commitment to scientific truth and patient well-being.
GEENIE is Guided, Efficient, and Effortless Navigation
GEENIE's proprietary platform is built around a uniquely engineered cell-penetrating protein nanoneedle. This technology allows therapeutic molecules to directly cross cell membranes without causing damage. By bypassing the endocytic route, GEENIE prevents endosomal trapping and delivers its payload straight to the cell’s cytosol.
GEENIE avoids the inefficient endosomal pathway, ensuring that drugs are not trapped in cellular compartments.
The negative charge and unique design of GEENIE makes it safe for use, reducing the risk of adverse immune reactions.
GEENIE can be engineered to recognize specific cell surface receptors, allowing precise delivery to diseased cells.
GEENIE enables lower functional doses by bypassing endosomes, improving delivery efficiency and minimizing side effects.
GEENIE enables lower functional doses by bypassing endosomes, improving delivery efficiency and minimizing side effects.
GEENIE delivers a broad spectrum of therapeutics, from small molecules to siRNA, ASOs, proteins and nucleic acids, offering flexible solutions for evolving needs.
GEENIE ensures precise and efficient delivery with tunable targeting to extrahepatic tissues, such as eye, lungs or the CNS. This significantly reduces off target exposure.
GEENIE ensures precise and efficient delivery with tunable targeting to extrahepatic tissues, such as eye, lungs or the CNS. This significantly reduces off target exposure.
Indication: Triple-negative breast cancer, glioblastoma
Cargo: nucleotide and protein-based therapies
Indication: Duchenne muscular dystrophy, Huntington's disease
Cargo: nucleotide-based therapies (e.g. siRNA, ASOS)
Indication: CNS therapies
Cargo: poorly soluble molecules for renewed therapeutic potential
CyGenica's pipeline is focused on leveraging GEENIE technology to address unmet needs in oncology & rare genetic disorders. Current projects include collaborations with biopharmaceutical companies to enhance the delivery of nucleotide and protein-based therapies.
Indication: Triple-negative breast cancer, glioblastoma
Cargo: nucleotide and protein-based therapies
Indication: Duchenne muscular dystrophy, Huntington's disease
Cargo: nucleotide-based therapies (e.g. siRNA, ASOS)
Indication: CNS therapies
Cargo: poorly soluble molecules for renewed therapeutic potential
CyGenica's pipeline is focused on leveraging GEENIE technology to address unmet needs in oncology & rare genetic disorders. Current projects include collaborations with biopharmaceutical companies to enhance the delivery of nucleotide and protein-based therapies.
Groundbreaking first nano molecular drill crosses cell membranes to safely deliver small molecules, biological therapeutics and nucleotide-based drugs.
https://www.nature.com/articles/d43747-021-00127-6
A GEENIE in a Bottle: CyGenica’s Unique Non-Viral Cargo Delivery Platform
https://crisprmedicinenews.com/news/a-geenie-in-a-bottle-cygenicas-unique-non-viral-cargo-delivery-platform/
Chief Executive Officer and Chairman of the Board
